Clinical activity of celecoxib in metastatic malignant melanoma
Clinical activity of celecoxib in metastatic malignant melanoma
复制标题
DOI：
10.1080/07357900601063790
复制
发表时间：
2006-12-01
影响因子：
2.4
通讯作者：
Wilson, Kenneth S.
中科院分区：
文献类型：
--
作者：
Wilson, Kenneth S.
环加氧酶-2 已在原发性和转移性黑色素瘤中得到证实，表明它可能具有功能性作用并成为潜在的治疗靶点。塞来昔布已被加拿大卫生部批准用于治疗家族性腺瘤性结肠息肉病，该药物被提供给 27 名手术无法治愈的复发性黑色素瘤患者，其中 87% 患有 M1c 期疾病。在该病例系列中，6 名患者之前接受过全身治疗，其中 1 名患者之前接受过 CancerVax。 7 名患者出现肿瘤消退（2 名完全消退，2 名部分消退，3 名混合稳定/部分缓解）。对于所有患者，从第一次无法治愈的转移开始的中位总生存时间为 31.9 个月，从塞来昔布开始使用到疾病进展和死亡的中位时间分别为 4.3 个月和 10.4 个月。有必要对塞来昔布治疗黑色素瘤进行进一步的临床评估。
Cyclo-oxygenase-2 has been demonstrated in primary and metastatic melanoma suggesting that it may have a functional role and be a potential therapeutic target. Celecoxib, which was approved by Health Canada for familial adenomatous polyposis coli, was offered to 27 patients with surgically incurable recurrent melanoma, 87 percent of whom had stage M1c disease. In this case series, 6 patients had received prior systemic therapy and one had prior CancerVax. Tumor regressions were seen in 7 patients (2 complete regressions, 2 partial regressions, and 3 mixed stable/partial response). For all patients, median overall survival time from first incurable metastasis was 31.9 months, and median times to progressive disease and death from start of celecoxib were 4.3 months and 10.4 months, respectively. Further clinical evaluation of celecoxib in melanoma is warranted.